7 completed, 2 terminated, 1 withdrawn. 4 Phase 2, 3 Phase 3, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Repligen Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity Secretin Synthetic Human (RG1068) - Pancreas Cancer | Early Phase 1 | Withdrawn | University Hospitals Cleveland Medical Center | 2011-06-01 | 2022-06-16 | |
| A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression RG2417, Placebo - Bipolar I Depression | Phase 2 | Completed | Repligen Corporation | 180 | 2008-11-01 | 2011-01-17 |
| Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas RG1068 (synthetic human secretin) - Pancreatitis | Phase 3 | Completed | Repligen Corporation | 258 | 2008-03-01 | 2009-12-03 |
| Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression Uridine - Bipolar Depression | Phase 2 | Completed | Repligen Corporation | 80 | 2006-03-01 | 2007-11-09 |
| Effects of RG1068 (Secretin) on Information Processing in Schizophrenia Subcutaneous Secretin - Schizophrenia | Phase 2 | Completed | Indiana University | 30 | 2005-11-01 | 2017-03-03 |
| Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder RG1068 (Synthetic Human Secretin) - Obsessive Compulsive Disorder (OCD) | Phase 2 | Completed | Indiana University | 12 | 2005-02-01 | 2024-02-23 |
| Safety of RG2077 in Patients With Multiple Sclerosis RG2077 (CTLA4-IgG4m) - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2003-01-01 | 2017-03-27 |
| Synthetic Human Secretin in Children With Autism RG1068 (Synthetic Human Secretin) - Autism | Phase 3 | Completed | Repligen Corporation | 2002-04-01 | 2005-08-05 | |
| Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction RG1068 (Synthetic Human Secretin) - Autism | Phase 3 | Terminated | Repligen Corporation | 2002-04-01 | 2005-11-21 | |
| RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease RG2133 (2',3',5'-tri-O-acetyluridine) - Mitochondrial Diseases | Phase 1 | Terminated | Repligen Corporation | 12 | 2005-08-05 |
Autistic Disorder (2) · Bipolar Disorder (2) · Ataxia (1) · Autoimmune Diseases (1) · Depression (1) · Mitochondrial Diseases (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Obsessive-Compulsive Disorder (1) · Pancreatic Neoplasms (1) · Pancreatitis (1) · Schizophrenia (1)
Secretin (5) · Uridine (2) · Sugars (1) · uridine triacetate (1)
United States (7)
Anantha Shekhar, MD, PhD (2) · David Jacoby, MD, PhD (1) · David R Jacoby, MD, PhD (1) · Gary Sachs, MD (1) · Pablo R Ros, MD MPH PhD (1) · Samia J. Khoury, MD (1)